Tuberculosis and Respiratory Diseases最新文献_第5页

Korean guidelines for diagnosis and management of interstitial lung diseases: Hypersensitivity pneumonitis. 韩国间质性肺疾病诊断和治疗指南：超敏性肺炎。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-03-06 DOI: 10.4046/trd.2024.0190

Byoung Soo Kwon, Sooim Sin, Kyung Hoon Kim, Jinkyeong Park, Beomsu Shin, Hongseok Yoo, Yong Hyun Kim

引用次数: 0

Efficacy of portable ultrasonography for early detection of pneumothorax following lung biopsy. 便携式超声波检查对早期发现肺活检后气胸的疗效。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-02-27 DOI: 10.4046/trd.2024.0178

Won Gun Kwack, Manbong Heo, Yeonseok Choi, Cheon Woong Choi, Byoung Soo Kwon, Yeon Wook Kim, Jong Sun Park, Young-Jae Cho, Jae Ho Lee, Sung Yoon Lim

{"title":"Efficacy of portable ultrasonography for early detection of pneumothorax following lung biopsy.","authors":"Won Gun Kwack, Manbong Heo, Yeonseok Choi, Cheon Woong Choi, Byoung Soo Kwon, Yeon Wook Kim, Jong Sun Park, Young-Jae Cho, Jae Ho Lee, Sung Yoon Lim","doi":"10.4046/trd.2024.0178","DOIUrl":"https://doi.org/10.4046/trd.2024.0178","url":null,"abstract":"Background: Pneumothorax is a notable complication of lung biopsy, and its early detection is crucial. This study aimed to compare the sensitivities of handheld portable lung ultrasonography and chest radiography for identifying early pneumothorax after lung biopsy.Methods: Both upright chest radiography and lung ultrasonography were performed 3 and 24 hours after lung biopsy. The disappearance of lung sliding and the appearance of lung points were considered evidence of pneumothorax on lung ultrasonography.Results: Of the 86 patients in this study, 23 were diagnosed with pneumothorax within 24 hours of biopsy. No significant differences were observed in sex, age, or baseline lung function between the pneumothorax and non-pneumothorax groups. The sensitivities of lung ultrasonography and chest radiography for pneumothorax detection were 73.9% and 47.8%, respectively, at 3 hours and 91.3% and 78.3%, respectively, at 24 hours. Furthermore, at 3 hours, the area under the curve for lung ultrasonography for diagnosing pneumothorax was significantly higher than that for chest radiography (0.870 vs. 0.739, p = 0.043); however, the difference was not significant at 24 hours (p = 0.254).Conclusion: These preliminary results show lung ultrasonography is more sensitive than chest radiography to detect early pneumothorax after lung biopsy and may be advantageous for the rapid diagnosis of pneumothorax.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Vaccination on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study. 接种疫苗对慢性阻塞性肺病急性加重的影响：一项基于全国人口的队列研究。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-02-27 DOI: 10.4046/trd.2024.0182

Sang Hyuk Kim, Hyun Lee, Min Ji Kim, Min Gu Kang, Jong Seung Kim, Jong Geol Jang, Youlim Kim, Hyeon-Kyoung Koo, Chin Kook Rhee, Kyung Hoon Min, Yong Il Hwang, Deog Kyeom Kim, Yong Bum Park, Ji-Yong Moon

{"title":"Effects of Vaccination on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study.","authors":"Sang Hyuk Kim, Hyun Lee, Min Ji Kim, Min Gu Kang, Jong Seung Kim, Jong Geol Jang, Youlim Kim, Hyeon-Kyoung Koo, Chin Kook Rhee, Kyung Hoon Min, Yong Il Hwang, Deog Kyeom Kim, Yong Bum Park, Ji-Yong Moon","doi":"10.4046/trd.2024.0182","DOIUrl":"https://doi.org/10.4046/trd.2024.0182","url":null,"abstract":"Background: Coronavirus 2019 (COVID-19) vaccination appears to have potential benefits for patients with chronic obstructive pulmonary disease (COPD). However, limited information is available on whether COVID-19 vaccination reduces acute exacerbation of COPD (AECOPD).Methods: In the present study, 41,606 individuals with COPD were enrolled using the Korean National Health Insurance System-severe acute respiratory syndrome coronavirus 2 (NHIS SARS-CoV-2) database from 2020-2021. A total of 3,602 individuals were included in the analytical cohort through 1:1 propensity score (PS) matching between vaccinated and unvaccinated individuals. The risk of AECOPD was assessed using a Cox proportional hazards regression analysis. A post hoc analysis assessed the impact of COVID-19 on AECOPD in vaccinated and unvaccinated individuals, adjusting for differences between infected and uninfected groups.Results: During the study period, the incidence of exacerbation was lower in vaccinated individuals (1,683/10,000 PY) than in unvaccinated individuals (3,410/10,000 PY). In the Cox proportional hazards regression model, the risk of AECOPD was significantly lower in vaccinated individuals compared to unvaccinated individuals (hazard ratio [HR) = 0.55, 95% confidence interval [CI] = 0.41-0.72). In the post hoc analysis, COVID-19 was associated with an increased risk of AECOPD among unvaccinated individuals after adjustment (adjusted HR = 2.06, 95% CI = 1.28-3.33). In contrast, among vaccinated individuals, the risk of AECOPD did not differ significantly between those infected and uninfected with COVID-19 (adjusted HR = 1.35, 95% CI = 0.42-4.36).Conclusion: COVID-19 vaccination may reduce the risk of AECOPD in individuals with COPD.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Characteristics of Chronic Obstructive Pulmonary Disease according to Smoking Status. 根据吸烟状况确定慢性阻塞性肺病的临床特征。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-10-30 DOI: 10.4046/trd.2024.0060

Joo Hun Park

{"title":"Clinical Characteristics of Chronic Obstructive Pulmonary Disease according to Smoking Status.","authors":"Joo Hun Park","doi":"10.4046/trd.2024.0060","DOIUrl":"10.4046/trd.2024.0060","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) can be caused by various factors, including lung infections, asthma, air pollution, childhood growth disorders, and genetic factors, though smoking is the predominant risk factor. The main pathological mechanisms in COPD involve small airway disease, emphysema, mucus hypersecretion, and vascular disorders. COPD in non-smokers is characterized by a normal 1-second forced expiratory volume decline, equal sex distribution, younger age of onset, fewer comorbidities, milder airflow obstruction, preserved diffusing capacity of the lungs for carbon monoxide, and radiological features such as more air-trapping and less severe emphysema compared to COPD in smokers. Nevertheless, non-smokers with COPD still experience a high prevalence of acute exacerbations, nearly equal to that of smokers with COPD. Moreover, COPD itself is an independent risk factor for developing lung cancer, regardless of smoking status. Given that COPD coexists with numerous comorbidities, effectively managing these comorbidities is crucial, requiring multifaceted efforts for comprehensive treatment.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"14-25"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Korean Guidelines for the Management and Antibiotic Therapy in Adult Patients with Hospital-Acquired Pneumonia. 韩国医院获得性肺炎成人患者管理和抗生素治疗指南》。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-10-11 DOI: 10.4046/trd.2024.0135

Hayoung Choi, Kyung Hoon Min, Young Seok Lee, Youjin Chang, Bo Young Lee, Jee Youn Oh, Ae-Rin Baek, Jongmin Lee, Kyeongman Jeon

{"title":"Korean Guidelines for the Management and Antibiotic Therapy in Adult Patients with Hospital-Acquired Pneumonia.","authors":"Hayoung Choi, Kyung Hoon Min, Young Seok Lee, Youjin Chang, Bo Young Lee, Jee Youn Oh, Ae-Rin Baek, Jongmin Lee, Kyeongman Jeon","doi":"10.4046/trd.2024.0135","DOIUrl":"10.4046/trd.2024.0135","url":null,"abstract":"Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are correlated with high morbidity and mortality rates. Guidelines that consider local epidemiologic data are fundamental for identifying optimal treatment strategies. However, Korea has no HAP/VAP guidelines. This study was conducted by a committee of nine experts from the Korean Academy of Tuberculosis and Respiratory Diseases Respiratory Infection Study Group using the results of Korean HAP/VAP epidemiologic studies. Eleven key questions for HAP/VAP diagnosis and treatment were addressed. The Convergence of Opinion on Suggestions and Evidence (CORE) process was used to derive suggestions, and evidence levels and recommendation grades were in accordance with the Grading of Recommendations Assessment Development and Evaluation (GRADE) methodology. Suggestions were made for the 11 key questions pertinent to diagnosis, biomarkers, antibiotics, and treatment strategies for adult patients with HAP/VAP. Using the CORE process and GRADE methodology, the committee generated a series of recommendations for HAP/VAP diagnosis and treatment in the Korean context.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"69-89"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Miliary Tuberculosis Associated with Klebsiella pneumonia: Managing the Double Whammy of Antimicrobial Resistance. 伴有克雷伯氏菌肺炎的睫状体结核病：抗菌药耐药性的双重打击。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-10-30 DOI: 10.4046/trd.2024.0105

Priyavardhan Mishra, Mohit Kondisetti, Anant Patil, Nikhil Sarangdhar, Vijaykumar Gupta

引用次数: 0

High-Dose Rifampicin for 3 Months after Culture Conversion for Drug-Susceptible Pulmonary Tuberculosis. 对药物敏感的肺结核进行培养转换后，大剂量利福平治疗 3 个月。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-09-27 DOI: 10.4046/trd.2024.0099

Nakwon Kwak, Joong-Yub Kim, Hyung-Jun Kim, Byoung-Soo Kwon, Jae Ho Lee, Jeongha Mok, Yong-Soo Kwon, Young Ae Kang, Youngmok Park, Ji Yeon Lee, Doosoo Jeon, Jung-Kyu Lee, Jeong Seong Yang, Jake Whang, Kyung Jong Kim, Young Ran Kim, Minkyoung Cheon, Jiwon Park, Seokyung Hahn, Jae-Joon Yim

{"title":"High-Dose Rifampicin for 3 Months after Culture Conversion for Drug-Susceptible Pulmonary Tuberculosis.","authors":"Nakwon Kwak, Joong-Yub Kim, Hyung-Jun Kim, Byoung-Soo Kwon, Jae Ho Lee, Jeongha Mok, Yong-Soo Kwon, Young Ae Kang, Youngmok Park, Ji Yeon Lee, Doosoo Jeon, Jung-Kyu Lee, Jeong Seong Yang, Jake Whang, Kyung Jong Kim, Young Ran Kim, Minkyoung Cheon, Jiwon Park, Seokyung Hahn, Jae-Joon Yim","doi":"10.4046/trd.2024.0099","DOIUrl":"10.4046/trd.2024.0099","url":null,"abstract":"Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen.Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156).Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups.Conclusion: The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"170-180"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Idiopathic Inflammatory Myopathies-Associated Interstitial Lung Disease in Adults. 成人特发性炎症性肌病相关间质性肺病

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-09-02 DOI: 10.4046/trd.2024.0072

Mitsuhiro Moda, Toyoshi Yanagihara, Ran Nakashima, Hiromitsu Sumikawa, Shigeki Shimizu, Toru Arai, Yoshikazu Inoue

{"title":"Idiopathic Inflammatory Myopathies-Associated Interstitial Lung Disease in Adults.","authors":"Mitsuhiro Moda, Toyoshi Yanagihara, Ran Nakashima, Hiromitsu Sumikawa, Shigeki Shimizu, Toru Arai, Yoshikazu Inoue","doi":"10.4046/trd.2024.0072","DOIUrl":"10.4046/trd.2024.0072","url":null,"abstract":"Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases characterized by muscle involvement and various extramuscular manifestations. Interstitial lung disease (ILD) is one of the most common extramuscular manifestations of IIM and is associated with significant mortality and morbidity. The clinical phenotypes, treatment responses, and prognosis of IIM-ILD are significantly related to myositis-specific antibody (MSA) profiles, with some racial differences. The features associated with MSA in IIM-ILD could also be relevant to cases of ILD where MSA is present but does not meet the criteria for IIM. The anti-melanoma differentiation-associated gene 5 antibody is highly associated with rapidly progressive ILD (RP-ILD), especially in Asian populations, and with characteristic cutaneous manifestations, such as skin ulcers. Radiologically, ground-glass opacities, consolidations, and nonsegmental linear opacities were more predominant than reticular opacities and honeycombing. While the mortality rate is still around 30%, the prognosis can be improved with early intensive therapy with corticosteroids and multiple immunosuppressants. In contrast, anti-aminoacyl-tRNA synthetase (ARS) antibodies are associated with chronic ILD, although RP-ILD is also common. Patients with anti-ARS antibodies often show lung-predominant presentations, with subtle muscle and skin involvement. Radiologically, reticular opacities, with or without consolidation, are predominant and may progress to honeycombing over time. Combination therapy with corticosteroids and a single immunosuppressant is recommended to prevent relapses, which often lead to a decline in lung function and fatal long-term outcomes. Significant advances in immunology and genetics holds promise for fostering more personalized approaches to managing IIMILD.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"26-44"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the Spirometry: New Diagnostic Modalities in Chronic Obstructive Pulmonary Disease. 肺活量测定之外：慢性阻塞性肺病的新诊断模式。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-09-23 DOI: 10.4046/trd.2024.0040

Jin Hwa Song, Youlim Kim

引用次数: 0

Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018-2021: A Nationwide Cross-Sectional Study. 2018-2021年韩国耐多药结核病和耐利福平单耐药结核病的临床概况：一项全国性横断面研究。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2025-01-01 Epub Date: 2024-09-23 DOI: 10.4046/trd.2024.0049

Jinsoo Min, Yousang Ko, Hyung Woo Kim, Hyeon-Kyoung Koo, Jee Youn Oh, Doosoo Jeon, Taehoon Lee, Young-Chul Kim, Sung Chul Lim, Sung Soon Lee, Jae Seuk Park, Ju Sang Kim

{"title":"Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018-2021: A Nationwide Cross-Sectional Study.","authors":"Jinsoo Min, Yousang Ko, Hyung Woo Kim, Hyeon-Kyoung Koo, Jee Youn Oh, Doosoo Jeon, Taehoon Lee, Young-Chul Kim, Sung Chul Lim, Sung Soon Lee, Jae Seuk Park, Ju Sang Kim","doi":"10.4046/trd.2024.0049","DOIUrl":"10.4046/trd.2024.0049","url":null,"abstract":"Background: This study aimed to identify the clinical characteristics of multidrug-resistant/ rifampicin-resistant tuberculosis (MDR/RR-TB) in the Republic of Korea.Methods: Data of notified people with tuberculosis between July 2018 and December 2021 were retrieved from the Korea Tuberculosis Cohort database. MDR/RR-TB was further categorized according to isoniazid susceptibility as follows: multidrug-resistant tuberculosis (MDR-TB), rifampicin-monoresistant tuberculosis (RMR-TB), and RR-TB if susceptibility to isoniazid was unknown. Multivariable logistic regression analysis was conducted to identify the factors associated with MDR/RR-TB.Results: Between 2018 and 2021, the proportion of MDR/RR-TB cases among all TB cases and TB cases with known drug susceptibility test results was 2.1% (502/24,447). The proportions of MDR/RR-TB and MDR-TB cases among TB cases with known drug susceptibility test results were 3.3% (502/15,071) and 1.9% (292/15,071), respectively. Among all cases of rifampicin resistance, 31.7% (159/502) were RMR-TB and 10.2% (51/502) were RR-TB. Multivariable logistic regression analyses revealed that younger age, foreigners, and prior tuberculosis history were significantly associated with MDR/ RR-TB.Conclusion: Rapid identification of rifampicin resistance targeting the high-risk populations, such as younger generations, foreign-born individuals, and previously treated patients are necessary for patient-centered care.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"159-169"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0